Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Schizoaffective Disorder
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with…
- Trial name
- NCT02237235
- Testing
- MMFS-202-302
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing…
- Trial name
- NCT00237809
- Testing
- D-serine, Cognitive Retraining (CRT)
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Psychosis, Psychotic Disorders
Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders
The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized.
- Conditions
- Psychosis, Psychotic Disorders, Primary Psychotic Disorders, Schizophrenia Spectrum Disorders
- Trial name
- KISO (NCT07395206)
- Testing
- Digital: Kiso Mind App
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Paranoia, Schizophrenia
Oxytocin Treatment of Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia.
- Conditions
- Paranoia, Schizophrenia, Schizoaffective Disorder
- Trial name
- OTS (NCT01028677)
- Testing
- intranasal spray with oxytocin, nasal spray without oxytocin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Smoking Relapse Prevention in Schizophrenia
This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Smokers
- Trial name
- NCT00320697
- Testing
- bupropion + nicotine patch + nicotine gum or lozenges
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia, Schizo Affective Disorder
Acetazolamide for Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
- Trial name
- APTS (NCT04887792)
- Testing
- Acetazolamide
- Where
- 2 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
Schizophrenia
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
- Trial name
- STAR-1 (NCT00509067)
- Testing
- Galantamine, CDP-choline, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Georgetown University
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Multifamily group psychoeducation [MFG] and group cognitive behavioral therapy [GCBT] are evidence-based treatments for first episode psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
- Trial name
- NCT01570972
- Testing
- Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Arizona
Bipolar I Disorder, Schizoaffective Disorder
Open Label Extension Study of NCT06221852
This is a 12-week open-label extension study for participants completing study NCT06221852.
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT06558201
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression
This study is aimed to evaluate the bipolar disorder symptoms in patients presented with schizophrenia, schizoaffective disorder or recurrent depression.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Recurrent Depression
- Trial name
- NCT01028196
- Where
- 3 sites in Russia
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Schizoaffective Disorder, Schizophrenia
Smoking Cessation for Veterans With Severe and Persistent Mental Illness
The investigators have developed an intervention called Behavioral Treatment of Smoking Cessation in SPMI (BTSCS), an innovative intervention that supplements pharmacotherapy and education with contingency management and a…
- Conditions
- Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
- Trial name
- NCT00960375
- Testing
- BTSCS, StSST
- Where
- 2 sites in United States
- Volunteers
- 179 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
Improving Accessibility and Personalization of CR for Schizophrenia
This project will explore adaptations of treatments for schizophrenia, with the goal of optimizing their effectiveness in real-world clinical settings and readiness for broad deployment.
- Trial name
- NCT03576976
- Testing
- Cognitive Remediation
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program
The purpose of this study is to determine if using a tablet computer, which is a very small, easy-to-carry computer, to practice thinking exercises at home will help improve your attention, memory, and problem solving abilities.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
- Trial name
- NCT03005574
- Testing
- TSW-HP, TSW-T
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Boston University Charles River Campus
Schizophrenia, Schizoaffective Disorder
Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone
The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone long-acting injectable.
- Trial name
- NCT00644852
- Testing
- Retrospective chart review study
- Volunteers
- 342 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Post-Traumatic Stress Disorder
Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses
This study will evaluate the effectiveness of tailored cognitive behavioral therapy in treating post-traumatic stress disorder in people with additional mental illnesses.
- Trial name
- NCT00494650
- Testing
- Cognitive behavioral therapy (CBT), Brief PTSD treatment
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
The aim of the project is to investigate the use of Raloxifene (a new form of estrogen) in the treatment of women with schizophrenia and schizoaffective disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- SERM (NCT00361543)
- Testing
- Raloxifene hydrochloride, Lactose Capsules
- Where
- Australia
- Volunteers
- 54 people
- Sponsor
- The Alfred
Schizophrenia, Schizo-affective Disorder
Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF-02545920 subjects with schizophrenia or schizo-affective disorder who are currently clinically stable and to evaluate the serum and urine pharmacokinetics of…
- Trial name
- NCT00463372
- Testing
- PF-02545920
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- Pfizer
Psychotic Disorders, Schizophrenia
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder
- Trial name
- FAST (NCT00486798)
- Testing
- Quetiapine, Rating Scales, Self Assessment Form
- Where
- 13 sites in Sweden
- Sponsor
- AstraZeneca